• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    10/9/24 9:01:54 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELEV alert in real time by email
    SC 13G/A 1 p24-2918sc13ga.htm ELEVATION ONCOLOGY, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Elevation Oncology, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001

    (Title of Class of Securities)
     

    28623U101

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 9 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 28623U10113G/APage 2 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empery Asset Management, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 28623U10113G/APage 3 of 9 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Ryan M. Lane

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

     

    CUSIP No. 28623U10113G/APage 4 of 9 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Martin D. Hoe

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 28623U10113G/APage 5 of 9 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Elevation Oncology, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 101 Federal Street, Suite 1900, Boston, MA 02110.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to the Common Stock (as defined in Item 2(d) below) of the Company:
       
      Investment Manager
       
      (i) Empery Asset Management, LP (the "Investment Manager"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants (as defined below) held by, funds to which the Investment Manager serves as investment manager (the "Empery Funds").
       
      Reporting Individuals
       
      (ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      (iii) Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is:
       
     

    1 Rockefeller Plaza, Suite 1205

    New York, New York 10020

     

    CUSIP No. 28623U10113G/APage 6 of 9 Pages

      

    Item 2(c). CITIZENSHIP:
       
      Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 (the "Common Stock")

     

    Item 2(e). CUSIP NUMBER:
       
      28623U101

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

      

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

     

    CUSIP No. 28623U10113G/APage 7 of 9 Pages

       
    Item 4. OWNERSHIP.
       
      The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 59,106,809 shares of Common Stock issued and outstanding as of August 2, 2024, as represented in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”) subject to the Blockers (as defined below).
       
      Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Blockers"), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers.  Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Warrants due to the Blockers.
       
      The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds.  Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds.  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.  Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

      

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

     

    CUSIP No. 28623U10113G/APage 8 of 9 Pages

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 28623U10113G/APage 9 of 9 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: October 9, 2024

       
      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
       
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane
      Ryan M. Lane
       
      /s/ Martin D. Hoe
      Martin D. Hoe

     

     

    Get the next $ELEV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELEV

    DatePrice TargetRatingAnalyst
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    1/3/2025Outperform
    William Blair
    5/31/2024$10.00Overweight
    Piper Sandler
    5/14/2024$8.00Overweight
    Stephens
    3/1/2024$7.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ELEV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

    BOSTON, June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (

    6/9/25 8:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

    -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, an

    5/15/25 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

    -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, b

    4/25/25 1:00:00 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevation Oncology downgraded by Stephens with a new price target

    Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

    3/24/25 8:34:27 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

    3/21/25 8:03:34 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology downgraded by Citizens JMP

    Citizens JMP downgraded Elevation Oncology from Mkt Outperform to Mkt Perform

    3/21/25 8:03:24 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    SEC Filings

    View All

    SEC Form 15-12G filed by Elevation Oncology Inc.

    15-12G - Elevation Oncology, Inc. (0001783032) (Filer)

    8/4/25 4:34:55 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Elevation Oncology Inc.

    EFFECT - Elevation Oncology, Inc. (0001783032) (Filer)

    7/29/25 12:15:02 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Elevation Oncology Inc.

    EFFECT - Elevation Oncology, Inc. (0001783032) (Filer)

    7/29/25 12:15:05 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sandler Alan B.

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:40:04 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mootz Darcy

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:35:04 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Elms Steve

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:30:06 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:05:59 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 6:45:37 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

    BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

    3/4/24 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

    BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

    1/22/24 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

    NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

    7/13/23 8:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Financials

    Live finance-specific insights

    View All

    Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

    -- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

    8/6/24 7:10:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

    -- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

    8/6/24 7:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

    Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod

    7/28/22 8:45:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care